Multiple sclerosis (MS) represents a chronic immune-mediated neurodegenerative disease of the central nervous system that generally debuts around the age of 20-30 years. Still, in recent years, MS has been increasingly recognized among the pediatric population, being characterized by several peculiar features compared to adult-onset disease. Unfortunately, the etiology and disease mechanisms are poorly understood, rendering the already limited MS treatment options with uncertain efficacy and safety in pediatric patients. Thus, this review aims to shed some light on the progress in MS therapeutic strategies specifically addressed to children and adolescents. In this regard, the present paper briefly discusses the etiology, risk factors, comorbidities, and diagnosis possibilities for pediatric-onset MS (POMS), further moving to a detailed presentation of current treatment strategies, recent clinical trials, and emerging alternatives. Particularly, promising care solutions are indicated, including new treatment formulations, stem cell therapies, and cognitive training methods.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179691PMC
http://dx.doi.org/10.3390/ijms24098251DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
8
state art
4
art pediatric
4
pediatric multiple
4
sclerosis multiple
4
sclerosis represents
4
represents chronic
4
chronic immune-mediated
4
immune-mediated neurodegenerative
4
neurodegenerative disease
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!